2026-06-04T23:55:15Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/453962026-02-13T00:45:26Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Labella, Marina author Nuñez, Rafael author Doña, Inmaculada author Rodríguez de Guzmán, Julia author Moreno, Esther author Garvey, Lene Heise author Laguna, Jose Julio author Barbaud, Annick author Bonnadona, Patrizia author Boel, Jonas Bredtoft author Mosbech, Holger author Sfriso, Giovanna author Castells, Mariana author Phillips, Elizabeth author Torres-Jaén, María Josefa author 2026 Background: A label of betalactam (BL) allergy is estimated in around 10% of the population in their medical records. Second-line choices carry significant negative consequences, including reduced efficacy, effectiveness, and safety. This study aimed todevelop a new highly specific score constructed by selecting variables assisted by artificial intelligence to identify low-risk BL-allergic patients.Methods: In this study, derivation and validation of the BL-predictor score were performed on a retrospective cohort of 2207patients who underwent penicillin allergy testing at Málaga University Hospital (Spain). The development of the BL-predictorencompassed expert drafting and a two-step variable selection process consisting of univariate analysis and variable filtering,followed by stepwise logistic regression with resampling. To assess the efficiency, a multicentric retrospective external valida-tion was performed in 4261 patients from six populations: Salamanca and Madrid, Spain; Nashville, United States of America;Verona, Italy; Paris, France; and Copenhagen, Denmark.Results: The definitive questionnaire consisted of eight items and risk points were computed from the logistic regression modelas follows: +1 for reactions after first dose or in less than 1 h (ITEM-1), +2 for anaphylaxis (ITEM-2); +1 for previous reaction withthe culprit (ITEM-3); −1 for resolution in > 24 h (ITEM- 4); +2 for spontaneous resolution (ITEM-5); −2 for unknown symptoms M. Labella, R. Nuñez, I. Doña, et al., “ Development of Betalactam-Predictor: A Clinical Decision Tool for Delabeling Low-Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy,” Allergy (2026): 1–13, https://doi.org/10.1111/all.70222. https://hdl.handle.net/10630/45396 https://doi.org/10.1111/all.70222 Alergia a los medicamentos Penicilina Anafilaxia Antibiogramas Development of Betalactam-Predictor: A clinical decision tool for delabeling low-risk Betalactam Allergy patients. Initial validation in penicillin allergy